PRODUCT INFORMATION

JQAD1

Item No. 39566

CAS Registry No.: 2417097-18-6
Formal Name: 12-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-((R)-3'-(2-((4-fluorobenzyl)((S)-1,1,1-trifluoropropan-2-yl)amino)-2-oxoethyl)-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-oxazolidin]-5-yl)dodecanamide
Synonym: (R,S)-JQAD1
MF: $C_{48}H_{52}F_4N_6O_9$
FW: 933.0
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

JQAD1 is supplied as a solid. A stock solution may be made by dissolving the JQAD1 in the solvent of choice, which should be purged with an inert gas. JQAD1 is soluble in DMSO.

Description

JQAD1 is a proteolysis-targeting chimera (PROTAC) composed of the p300 and CREB-binding protein (CBP) inhibitor A-485 (Item No. 24119) conjugated to a cereblon (CRBN) ligand.[1] It selectively induces the degradation of p300 over CBP in Kelly MYCN-amplified neuroblastoma cells when used at a concentration of 10 µM for 24 hours. JQAD1 (0.5 µM) decreases histone 3 lysine 27 (H3K27) acetylation and induces apoptosis in Kelly cells. *In vivo*, JQAD1 (40 mg/kg) decreases tumor volume, increases survival, and reduces tumoral p300 but not CBP levels in a Kelly neuroblastoma mouse xenograft model.

Reference

1. Durbin, A.D., Wang, T., Wimalasena , V.K., *et al.* EP300 selectively controls the enhancer landscape of MYCN-amplified neuroblastoma. *Cancer Discov.* **12(3)**, 730-751 (2022).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM